

Company Number: 685538

Cafa Therapeutics Limited

Abridged Unaudited Financial Statements

for the financial period from 1 January 2023 to 31 December 2023

Cafa Therapeutics Limited  
CONTENTS

	Page
Director' s Responsibilities Statement	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 9

Cafa Therapeutics limited

## DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial period from 1 January 2023 to 31 December 2023

The director made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial period. Under the law the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial period end date and of the profit or loss of the company for the financial period and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent.
- state whether the financial statements have been prepared in accordance with applicable accounting standards identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable him to ensure that the financial statements and Director's Report comply with the Companies Act 2014. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Director's declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Statement of Changes in Equity and notes:

The director approves these financial statements and confirms that he is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that to the best of his knowledge and belief, the accounting records reflect all the transactions of the company for the financial period from 1 January 2023 (date of incorporation) to 31 December 2023."

### Signed on behalf of the board

Zonghai Li

Director

17 August 2023

## Cafa Therapeutics Limited

## BALANCE SHEET

As at 31 December 2023

	Notes	2023 Y US\$
<b>Fixed Assets</b>		
Intangible assets	9	0
		-----
<b>Current Assets</b>		
Debtors	10	1,000
Trading receivable from related parties		2,182,994
Cash and cash equivalents		0
		-----
		2,183,994
<b>Creditors: Amount falling due within one year</b>	11	0
		-----
<b>Net Current Liabilities</b>		2,183,994
		-----
<b>Total Assets less Current Liabilities</b>		2,183,994
		=====
<b>Capital and Reserves</b>		
Called up share capital presented as equity	13	1,000
Retained earnings		2,182,994
		-----
<b>Equity attributed to owned of the company</b>		2,183,994
		=====

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Cafa Therapeutics Limited, state that –

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014.
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied.
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2)
- (d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial period and of its profit or loss for such a financial period and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 17 August 2023 and signed on its behalf by:

Zonghai Li  
Director

Cafa Therapeutics Limited  
STATEMENT OF CHANGES IN EQUITY  
As at 31 December 2023

	2023 Y US\$
Profit for the financial period	-136,024
	-----
At 31 December 2023 Y	-136,024
	=====

## **Cafa Therapeutics Limited**

### **NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial period from 1 January 2023 to 31 December 2023

#### **1. General information**

Cafa Therapeutics Limited is a company limited by shares incorporated and registered in the Republic of Ireland. The registered number of the company is 685538. The registered office of the company is 2/3 Exchange Place, IFSC, Dublin, Dublin 1, D01AE27. Ireland which is also the principal place of business of the company. The Principal Activity of the Company is that of Experimental Development on Biotechnology. The financial statements have been presented in US Dollar (US\$) which is also the functional currency of the company.

#### **2. Summary of Significant Accounting Policies**

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

#### **Statement of compliance**

The financial statements of the company for the financial period ended 31 December 2023 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014. These are the company's first set of financial statements prepared in accordance with FRS 102.

#### **Basis of preparation**

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial period and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### **Turnover**

Turnover comprises of patent income received by the company, exclusive of trade discounts and value added tax.

#### **Trade and other debtors**

Trade and other debtors are initially recognized at fair value and thereafter stated at amortized cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

#### **Trade and other creditors**

Trade and other creditors are initially recognized at fair value and thereafter stated at amortized cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

#### **Taxation and deferred taxation**

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial period and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognized in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

### Research and development

Research expenditure is written off to the Profit and Loss Account in the financial period in which it is incurred. Development expenditure is written off in the same financial period unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortized over the period from which the company is expected to benefit.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

### 3. Adoption of FRS 102

This is the first set of financial statements prepared by Cafá Therapeutics Limited in accordance with accounting standards issued by the Financial Reporting Council, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A (Small Entities).

### 4. Period of financial statements

The financial statements are for the 12 months from 1 January 2023 to 31 December 2023.

### 5. Statement on previous periods

The company presents financial statements for previous periods

### 6. Turnover

The turnover for the financial period is 0

### 7. Operating profit

Operating profit is stated as follows:

	2023 Y
	US\$
Profit for the financial period	-136,024

### 8. Employees

The average monthly number of employees, including director, during the financial period was 1. (2023 - 1).

Cafa Therapeutics Limited  
 NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

continued

for the financial period from 1 January 2023 to 31 December 2023

9. Intangible assets

	Development Cost US\$	Total US\$
Cost		
At 1 January 2023 Y	0	0
Decrease	0	0
	-----	-----
At 31 December 2023 Y	0	0
	-----	-----
Net book value		
At 31 December 2023 Y	0	0
	=====	=====

10. Debtors

	2023 Y US\$
Other debtors	1,000
	-----
	1,000
	=====

11. Creditors

	2023 Y US\$
Amount failing due within one year	
Trade creditors	0
Amounts owed to group undertakings	0
Amounts owed to related parties	0
Taxation	0
Accruals	0
	-----
	0

12. Taxation

	2023 Y US\$
Corporation Tax	133,127

13. Share capital

Description	Number of Shares	Value of units	2023 Y US\$
Authorised			
\$1 Ordinary Share	1000	US\$1 each	1,000
			=====
Allotted, called up and fully paid			
\$1 Ordinary Share	1000	US\$1 each	1,000
			=====

No director or the secretary had an interest in the share capital of the company at any time during the financial period.

for the financial period from 1 January 2023 to 31 December 2023

**14. Profit and loss account**

	2023 Y
	US\$
Profit for the financial period	-136,024
	-----
At 31 December 2023 Y	-136,024
	=====

**15. Capital commitments**

The company had no material capital commitments at the financial period ended 31 December 2023.

**16. Related party transactions**

	2023 Y
	US\$
Net balances with related parties:	
Trading receivable from related parties	2,182,994
Trading amounts owed to related parties	0
	=====

**17. Parent and ultimate parent company**

The company regards Panzenith Biotech Limited as its parent company. The company's ultimate parent undertaking is CARsgen Therapeutics Holdings Limited. The address of CARsgen Therapeutics Holdings Limited is 5/F Manulife Place 348 Kwun Tong Road KowloonHong Kong.

**18. Post-Balance Sheet Events**

There have been no significant events affecting the company since the financial period-end

**19. Approval of financial statements**

The financial statements were approved and authorized for issue by the board on 17 August 2023